Qatar MOPH issues new Guideline on Braille Requirements for Labeling Information of Medicinal Products for Human Use

🔍 What’s new:
The Pharmacy & Drug Control Department (PDCD) under Qatar’s Ministry of Public Health has released a comprehensive guideline specifying mandatory Braille labeling requirements for all human medicinal products.

Key highlights include:
• The name of the medicinal product followed by its strength should be put in Braille on the packaging of the product.
• Standardized Braille transcription to be printed in Arabic / English language and the readability must not be compromised.
• A Braille Declaration must be provided on company letter headed paper, signed, and dated by applicants. The wording to be provided in Braille will be assessed in line with the requirements of Qatar MOPH guidelines.
• Exemptions and justification process for products with technical or space constraints.
• Implementation timelines will be in 2nd of Sep 2027.

💡 Why it matters:
This initiative reinforces Qatar’s commitment to patient accessibility, inclusivity, and universal health equity. Pharmaceutical companies will need to align their packaging design and regulatory submissions with these updated labeling requirements before marketing authorization or renewal.

📌 How ReguLinked can support you:
• Review and adapt your product packaging to meet Braille and accessibility requirements
• Assist with label artwork, translation, and regulatory submission under PDCD guidelines

📨 Need help ensuring your product labeling meets Qatar’s new accessibility standards?
Let’s make your compliance journey inclusive, efficient, and market-ready.

Book your complimentary consultation today

📧 BD@regulinked.com | 🌐 www.regulinked.com

📎 Attached the official update here: Guideline on the Braille Requirements

#Qatar #MoPH #RegulatoryUpdate #PharmaCompliance #Labeling #Braille #Accessibility #GCCRegulations #ReguLinked #MarketAccess #Pharmaceuticals #QatarHealthcare